Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) CEO Joseph C. Papa purchased 30,000 shares of the company’s stock in a transaction on Tuesday, March 13th. The stock was acquired at an average price of $16.05 per share, for a total transaction of $481,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) traded up $0.29 on Tuesday, hitting $16.08. The stock had a trading volume of 8,569,076 shares, compared to its average volume of 12,640,000. The firm has a market cap of $5,600.00, a P/E ratio of 3.95, a price-to-earnings-growth ratio of 0.52 and a beta of -0.28. Valeant Pharmaceuticals Intl Inc has a one year low of $8.31 and a one year high of $24.43. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 4.25.
Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last issued its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. The company had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.18 billion. Valeant Pharmaceuticals Intl had a return on equity of 42.48% and a net margin of 27.56%. The firm’s quarterly revenue was down 10.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.26 EPS. equities analysts predict that Valeant Pharmaceuticals Intl Inc will post 3.12 earnings per share for the current year.
Several institutional investors and hedge funds have recently modified their holdings of VRX. Northern Trust Corp increased its holdings in shares of Valeant Pharmaceuticals Intl by 63.7% in the 2nd quarter. Northern Trust Corp now owns 326,013 shares of the specialty pharmaceutical company’s stock valued at $5,640,000 after purchasing an additional 126,851 shares during the period. Nationwide Fund Advisors increased its holdings in shares of Valeant Pharmaceuticals Intl by 25.0% in the 3rd quarter. Nationwide Fund Advisors now owns 65,480 shares of the specialty pharmaceutical company’s stock valued at $938,000 after purchasing an additional 13,080 shares during the period. Crossmark Global Holdings Inc. acquired a new position in shares of Valeant Pharmaceuticals Intl in the 3rd quarter valued at about $490,000. Andra AP fonden increased its holdings in shares of Valeant Pharmaceuticals Intl by 35.0% in the 3rd quarter. Andra AP fonden now owns 98,800 shares of the specialty pharmaceutical company’s stock valued at $1,767,000 after purchasing an additional 25,600 shares during the period. Finally, Gabelli Funds LLC increased its holdings in shares of Valeant Pharmaceuticals Intl by 49.3% in the 3rd quarter. Gabelli Funds LLC now owns 91,088 shares of the specialty pharmaceutical company’s stock valued at $1,305,000 after purchasing an additional 30,088 shares during the period. Institutional investors own 50.12% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Valeant Pharmaceuticals Intl Inc (VRX) CEO Joseph C. Papa Purchases 30,000 Shares” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://sportsperspectives.com/2018/03/13/valeant-pharmaceuticals-intl-inc-vrx-ceo-joseph-c-papa-purchases-30000-shares.html.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.